Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol

Anti-Cancer Drugs

Volumn 23, Issue 5, 2012, Pages 515-524

  Huang, Yulun ^a,c   Zhou, Dai ^a   Hang, Taijun ^b   Wu, Zhenghong ^b   Liu, Jiangang ^a   Xu, Qinan ^a   Xie, Xuesun ^a   Zuo, Jianling ^a   Wang, Zhong ^a   Zhou, Youxin ^a  

^a SOOCHOW UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

animal xenografts model; celastrol; encapsulation efficiency; glioma; liposomal; pharmacokinetics; side effect; tissue distribution

Indexed keywords

CELASTROL; CISPLATIN; HEMOGLOBIN; LIPOSOME; SULFORHODAMINE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENCAPSULATION; ERYTHROCYTOSIS; FEMALE; GLIOMA; HUMAN; IC 50; LEUKOCYTOSIS; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BRAIN NEOPLASMS; CELL SURVIVAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; GLIOMA; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862798178     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283514b68     Document Type: Article

References (27)

1. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66:4758-4765.
2. Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res 2007; 13:6769-6778. (Pubitemid 350206815)
3. Jang SY, Jang SW, Ko J. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett 2011; 300:57-65.
4. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7:162-170.
5. Mou H, Zheng Y, Zhao P, Bao H, Fang W, Xu N. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria-and Fas/FasL-mediated pathways. Toxicol In Vitro 2011; 25:1027-1032.
6. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008; 264:101-106.
7. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 2009; 284: 35381-35389.
8. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009; 8: 2339-2347.
9. Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, et al. Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther 2010; 334:489-499.
10. Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 1993; 46:618-638.
11. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88:11460-11464. (Pubitemid 21916061)
12. Ferreira H, Lucio M, Lima JL, Matos C, Reis S. Interaction of clonixin with EPC liposomes used as membrane models. J Pharm Sci 2005; 94:1277-1287. (Pubitemid 40904191)
13. Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, et al. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res 2007; 13:4891-4899. (Pubitemid 47294797)
14. Ushiro S, Ono M, Nakayama J, Fujiwara T, Komatsu Y, Sugimachi K, et al. New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization. Int J Cancer 1997; 72:657-663. (Pubitemid 27356169)
15. Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, et al. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010; 5:e14153.
16. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006; 72:1311-1321. (Pubitemid 44572192)
17. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010; 70:1951-1959.
18. Peng B, Xu L, Cao F, Wei T, Yang C, Uzan G, et al. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer 2010; 9:79.
19. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007; 109:2727-2735. (Pubitemid 46482064)
20. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007; 18:26-30. (Pubitemid 46227971)
21. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998; 56:747-756.
22. Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems - clinical applications. Acta Pharm 2005; 55:1-25. (Pubitemid 40562616)
23. Metselaar JM, Mastrobattista E, Storm G. Liposomes for intravenous drug targeting: design and applications. Mini Rev Med Chem 2002; 2: 319-329.
24. Bangham AD, Standish MM,Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13:238-252.
25. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95:4607-4612. (Pubitemid 28207960)
26. Scherphof GL, Dijkstra J, Spanjer HH, Derksen JT, Roerdink FH. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann N Y Acad Sci 1985; 446: 368-384. (Pubitemid 16238580)
27. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995; 1235: 296-304.